Staying updated on the mobile price list is essential for anyone in search of the latest smartphone deals, especially when it comes to Vivo phones in India. Vivo releases new models, offering a wide ...

Vivo V40 mobile was launched on 7th August 2024. The phone comes with a 120 Hz refresh rate 6.78-inch display offering a resolution of 1260x2800 pixels. It comes with 8GB, 12GB of RAM. The Vivo V40 ...

These are just a few of the many great smartphones available Vivo under 35000 price in pakistan. When choosing a Vivo smartphone, it is important to consider your needs and budget. If you are looking ...

The Vivo Y300 5G features a 6.67-inch (2400 ×1080 pixels) Full HD+ E4 AMOLED screen with a 120Hz refresh rate. It is powered by the Snapdragon 4 Gen 2 processor paired with 8GB RAM and up to ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months ...

VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for ...

在最新一届珠海航展即将开幕之际，一张带有“YJ-21E”标志的模糊图片，在国内社交媒体上引起发高度关注。虽然官方还未对此正式表态，但大多数舆论对于这款刚刚在今年4月现身的划时代兵器，立即被“摆上货架”感到极为震惊。而事实上，鹰击-21E现身航展 ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...

Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of ...

AC Immune SA reported its full-year financial results for 2024, highlighting significant advancements in its pipeline and a landmark partnership with Takeda for the immunotherapy ACI-24.060, which ...

ACI-19764 small molecule NLRP3 inhibitor is undergoing in vivo proof of concept with results expected in 2025 anticipated to enable investigational new drug (IND) application. Our Morphomer Tau ...